BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28429175)

  • 1. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3.
    Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW
    J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3.
    Xie C; Tiede C; Zhang X; Wang C; Li Z; Xu X; McPherson MJ; Tomlinson DC; Xu W
    Sci Rep; 2017 Aug; 7(1):9608. PubMed ID: 28852111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma.
    Zhang Q; Xiao Q; Lin Z; Ying X; Li Z; Lin JM
    Clin Biochem; 2010 Aug; 43(12):1003-8. PubMed ID: 20444424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis.
    Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M
    Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
    Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
    Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
    Nishimura Y; Nakatsura T; Senju S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma.
    Yu JP; Xu XG; Ma RJ; Qin SN; Wang CR; Wang XB; Li M; Li MS; Ma Q; Xu WW
    J Clin Lab Anal; 2015 Mar; 29(2):85-93. PubMed ID: 24687454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
    Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
    Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glypican-3: a new target for cancer immunotherapy.
    Ho M; Kim H
    Eur J Cancer; 2011 Feb; 47(3):333-8. PubMed ID: 21112773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
    Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
    Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma.
    Nakatsura T; Nishimura Y
    BioDrugs; 2005; 19(2):71-7. PubMed ID: 15807627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
    Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
    Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
    Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
    Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
    Kandil DH; Cooper K
    Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
    Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
    Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of monoclonal antibody against glypican-3.
    Ma RJ; Wang SH; Qin SN; Wang XB; Li GF; Li M; Xu WW
    Hybridoma (Larchmt); 2012 Dec; 31(6):455-61. PubMed ID: 23244326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
    Li J; Wei L
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
    Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
    Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.